Thu Sep 19 06:23:09 UTC 2024: ## Insulet Stock Soars on Analyst Upgrades, Positive Outlook

**Boston, MA -** Medical instruments supplier Insulet (NASDAQ:PODD) saw its stock price jump after analysts at Piper Sandler raised their price objective from $230 to $285, representing a potential upside of 20.71%. The firm maintained an “overweight” rating on the stock, highlighting a positive outlook for the company.

This bullish sentiment is echoed by several other analysts. Redburn Atlantic initiated coverage with a “buy” rating and a $235 price objective, while BTIG Research lowered its target to $250 but retained a “buy” rating. Canaccord Genuity Group also reaffirmed their “buy” rating with a $234 price objective.

While UBS Group maintained a “neutral” rating, they raised their target price from $211 to $223. Barclays also increased their target from $200 to $220 but gave the stock an “equal weight” rating. Overall, Insulet currently enjoys a “Moderate Buy” consensus rating with a target price of $229.21, based on the analysis of 16 analysts.

Insulet’s recent quarterly earnings report, released on August 8th, showed revenue of $488.50 million, slightly exceeding analysts’ estimates. While earnings per share came in slightly below expectations at $0.55, the company demonstrated strong growth with a 23.2% increase in revenue compared to the previous year.

Several institutional investors have also shown confidence in Insulet. Orion Portfolio Solutions LLC significantly increased its stake in the company by 276.6%, while Diversified Trust Co boosted its holdings by 90.9%. Other notable investors include SG Americas Securities LLC and Allianz Asset Management GmbH, who also raised their positions in the company.

Insulet’s focus on developing innovative insulin delivery systems for people with diabetes, such as the Omnipod 5 Automated Insulin Delivery System, continues to drive growth and attract investor interest. The company’s strong financial performance and positive analyst sentiment suggest a bright future for Insulet, with the potential for continued stock appreciation.

Read More